FLUI Stock Overview
Operates as a life science company, provides platforms and research solutions for bioprinting and single-cell biology. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Fluicell AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.058 |
| 52 Week High | SEK 1.10 |
| 52 Week Low | SEK 0.041 |
| Beta | 1.77 |
| 11 Month Change | -12.61% |
| 3 Month Change | -36.60% |
| 1 Year Change | -91.92% |
| 33 Year Change | -99.76% |
| 5 Year Change | -99.35% |
| Change since IPO | -99.62% |
Recent News & Updates
Shareholder Returns
| FLUI | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | -2.7% | -2.6% | -0.2% |
| 1Y | -91.9% | -6.3% | 11.8% |
Return vs Industry: FLUI underperformed the Swedish Medical Equipment industry which returned -6.3% over the past year.
Return vs Market: FLUI underperformed the Swedish Market which returned 11.8% over the past year.
Price Volatility
| FLUI volatility | |
|---|---|
| FLUI Average Weekly Movement | 11.3% |
| Medical Equipment Industry Average Movement | 7.5% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in SE Market | 11.2% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: FLUI's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: FLUI's weekly volatility has decreased from 29% to 11% over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 11 | Carolina Trjulja | www.fluicell.com |
Fluicell AB (publ) operates as a life science company, provides platforms and research solutions for bioprinting and single-cell biology. The company offers BIOPEN, a microfluidic platform for high-precision single-cell solution delivery that enables to control the cell microenvironment without moving or disturbing the cells; Biozone 6 that generate dose-response curves or study the effects of multiple drug compounds; and Dynaflow Resolve system, an ion channel screening platform, which allows to record various ion channel current in patch-clamp recording configuration. It also provides Biopixlar, a 3D single-cell bioprinting platform that enables high cell viability and cell-to-cell communication; and Biopixlar AER, an easy-to-use 3D bioprinting platform that fits into your fume hood or biosafety cabinet.
Fluicell AB (publ) Fundamentals Summary
| FLUI fundamental statistics | |
|---|---|
| Market cap | SEK 27.98m |
| Earnings (TTM) | -SEK 22.14m |
| Revenue (TTM) | SEK 4.82m |
5.8x
P/S Ratio-1.3x
P/E RatioIs FLUI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FLUI income statement (TTM) | |
|---|---|
| Revenue | SEK 4.82m |
| Cost of Revenue | SEK 1.45m |
| Gross Profit | SEK 3.36m |
| Other Expenses | SEK 25.50m |
| Earnings | -SEK 22.14m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 21, 2025
| Earnings per share (EPS) | -0.046 |
| Gross Margin | 69.84% |
| Net Profit Margin | -459.62% |
| Debt/Equity Ratio | 0% |
How did FLUI perform over the long term?
See historical performance and comparison